Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial)

Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial

(2014) Adriana H Tremoulet et al.   LANCET

Epidemiology of Immunoglobulin Resistant Kawasaki Disease: Results from a Large, National Database

(2014) Brady S. Moffett et al.   PEDIATRIC CARDIOLOGY

Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial

(2012) Tohru Kobayashi et al.   LANCET

Ulinastatin, a Urinary Trypsin Inhibitor, for the Initial Treatment of Patients With Kawasaki Disease

(2011) Takashi Kanai et al.   CIRCULATION

Cyclosporin A Treatment for Kawasaki Disease Refractory to Initial and Additional Intravenous Immunoglobulin

(2011) Hiroyuki Suzuki et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

ITPKC and CASP3 polymorphisms and risks for IVIG unresponsiveness and coronary artery lesion formation in Kawasaki disease

(2011) Y Onouchi et al.   PHARMACOGENOMICS JOURNAL

Common variants in CASP3 confer susceptibility to Kawasaki disease

(2010) Yoshihiro Onouchi et al.   HUMAN MOLECULAR GENETICS

Epidemiologic Features of Kawasaki Disease in Japan: Results of the 2007–2008 Nationwide Survey

(2010) Yosikazu Nakamura et al.   JOURNAL OF EPIDEMIOLOGY

Resistance to Intravenous Immunoglobulin in Children with Kawasaki Disease

(2008) Adriana H. Tremoulet et al.   JOURNAL OF PEDIATRICS